| Literature DB >> 32154023 |
Joaquin Duarte Ow1, Mohamad Hemu2, Anel Yakupovich2, Parva Bhatt2, Hannah Gaddam3, Nicole Prabhu2, Ibtihaj Fughhi2, Melody Cobleigh4, Melissa Tracy5, Louis Fogg6, Tochukwu Okwuosa5.
Abstract
INTRODUCTION: Assessment of cardiac function after treatment for breast cancer relies on interval evaluation of ventricular function through echocardiography. Women who undergo mastectomy more frequently choose to undergo breast reconstruction with implant. This could impede assessment of cardiac function in those with left-sided implant. We aimed to examine whether left-sided breast reconstruction with tissue expanders (TE) affect echo image acquisition and quality, possibly affecting clinical decision-making.Entities:
Keywords: Breast reconstruction; Echocardiogram; Image quality; Tissue expander
Year: 2019 PMID: 32154023 PMCID: PMC7048107 DOI: 10.1186/s40959-019-0052-7
Source DB: PubMed Journal: Cardiooncology ISSN: 2057-3804
Fig. 1Patient selection
Baseline characteristics
| Left/Bilateral TE | Right/No recontstruction TE | ||||
|---|---|---|---|---|---|
| Race | 0.738 | ||||
| Non-white | (6) | 18.7% | (37) | 23.4% | |
| White | (26) | 81.3% | (121) | 76.6% | |
| Age at dx | 48 ± 12.4 | 57.5 ± 11.1 |
| ||
| Breast Cancer | |||||
| Primary side | |||||
| Right | (9) | 28.2% | (74) | 46.8% | |
| Left | (23) | 71.8% | (79) | 50% | |
| Bilateral | (1) | 2% | (5) | 3.2% | |
| Size |
| ||||
| 2–5 cm | (8) | 25% | (40) | 25.3% | |
| > 5 cm | (5) | 15.6% | (6) | 3.7% | |
| Chest or skin invasion | (1) | 3.2% | (1) | 0.6% | |
| Not specified | (1) | 3.2% | (9) | 5.6% | |
| Node status | 0.329 | ||||
| N0 | (14) | 43.7% | (83) | 52.5% | |
| N1 | (18) | 56.3% | (73) | 46.2% | |
| Grade | 0.633 | ||||
| I | (3) | 9.4% | (22) | 14.2% | |
| II | (18) | 25% | (41) | 26.5% | |
| III | (16) | 50% | (56) | 36.1% | |
| Not specified | (7) | 15.6% | (36) | 23.2% | |
| TE side | |||||
| Left | (14) | 7.4% | |||
| Right | (7) | 3.4% | |||
| Bilateral | (18) | 9.4% | |||
| No reconstruction | (151) | 79.4% | |||
| Treatment | |||||
| Anthracyclines | (28) | 90.2% | (104) | 70.7% |
|
| Antiestrogen | (25) | 78.1% | (100) | 68% | 0.248 |
| Trastuzumab | (29) | 90.6% | (105) | 70.9% |
|
| Radiation Therapy | (29) | 90.6% | (104) | 71.2% |
|
| ECHO | |||||
| LVEF | 58 ± 5 | 58 ± 7 | 0.913 | ||
| BMI | 26.9 ± 5.4 | 28.7 ± 7.3 | 0.242 | ||
| SBP | 123 ± 18 | 131 ± 22 | 0.051 | ||
| DBP | 71 ± 10 | 73 ± 12 | 0.350 | ||
| Comorbidities | |||||
| COPD | – | (8) | 5% |
| |
| Prior Chest surgery | (3) | 9.7% | (13) | 8.4% | 0.826 |
| HTN | (16) | 51.6% | (87) | 56.5% | 0.618 |
| DM | (3) | 9.4% | (25) | 16.2% | 0.300 |
| Dyslipidemia | (8) | 25% | (49) | 32% | 0.427 |
| Heart failure | (2) | 6.5% | (17) | 11% | 0.419 |
| CKD | (1) | 3.2% | (4) | 2.6% | 0.852 |
| CAD | (1) | 3.2% | (17) | 11% | 0.278 |
| Obesity | (17) | 32.7% | (73) | 36.9% | 0.879 |
| Medications | |||||
| ASA | (7) | 21.9% | (45) | 29.2% | 0.390 |
| ACE/ARB | (8) | 25% | (38) | 24.7% | 0.969 |
| Beta blocker | (8) | 25% | (47) | 30.5% | 0.528 |
| Statin | (9) | 28.1% | (44) | 28.8% | 0.942 |
| Smoking | 0.615 | ||||
| Never smoker | (16) | 53.3% | (80) | 57.6% | |
| Former Smoker | (11) | 36.7% | (52) | 37.4% | |
| Active Smoker | (3) | 10% | (7) | 5.9% | |
*p values < 0.05 are listed in boldface
Technician and cardiologists assessment scalea
| Technical difficulty (Technicians) | Image quality (Cardiologists) |
|---|---|
| Excellent | Excellent |
| Good | Good |
| Adequate | Fair |
| Technically difficult | Poor |
aTechnicians assess technical difficulty of image acquisition, cardiologists assess image quality
Fig. 2Image Quality As Assessed by Technician or Cardiologist in Patients with Tissue Expanders*.*Adjusted for age, tumor size, COPD status and cancer treatment received. § Parentheses represents image quality by cardiologists
Image quality ratingsa
| Technician | Cardiologist | |||
|---|---|---|---|---|
| Excellent/Good | Adequate/ technically difficult | Excellent/Good | Fair/Poor | |
| Left/Bilateral | 9.4% | 90.6% | 31.8% | 68.2% |
| Right/None | 29.1% | 70.9% | 51.2% | 48.8% |
Adjusted for age, tumor size, COPD status and treatment received (anthracyclines, radiotherapy and trastuzumab
aExpressed as percentage of cases or controls